Validity of claims‐based definitions of left ventricular systolic dysfunction in Medicare patients

Ejection fraction (EF) is crucial information when studying the use and effectiveness of therapies in patients with heart failure (HF) and myocardial infarction (MI). We aimed to assess the validity of claims data‐based definitions of systolic dysfunction (SD).

[1]  Fibrillation atriale et insuffisance cardiaque : une redoutable association de malfaiteurs , 2009 .

[2]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[3]  Hude Quan,et al.  Administrative data have high variation in validity for recording heart failure. , 2010, The Canadian journal of cardiology.

[4]  Perry M. Elliott,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[5]  D A Savitz,et al.  Estimating and correcting for confounder misclassification. , 1989, American journal of epidemiology.

[6]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[7]  Adrian F Hernandez,et al.  Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. , 2009, American heart journal.

[8]  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001 .

[9]  J. Avorn,et al.  Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. , 2008, American heart journal.

[10]  S. Schneeweiss.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[11]  K. Schulman,et al.  Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. , 2007, JAMA.

[12]  R. Harrison,et al.  Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment. , 2001, American family physician.

[13]  N. Dreyer,et al.  Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data , 2011, Clinical pharmacology and therapeutics.

[14]  Peter C Austin,et al.  Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. , 2007, Journal of the American College of Cardiology.

[15]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[16]  A. Tsiatis,et al.  Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.

[17]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[18]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[19]  Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. , 2008, International journal of cardiology.

[20]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[21]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[22]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[23]  N. Dreyer,et al.  Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data , 2011, Clinical pharmacology and therapeutics.

[24]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[25]  R. Gliklich,et al.  Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.

[26]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[27]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[28]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[29]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[30]  J. Avorn,et al.  Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. , 2008, Journal of the American College of Cardiology.

[31]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[32]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[33]  K. Bailey,et al.  Clinical criteria and biochemical markers for the detection of systolic dysfunction. , 2000, Journal of cardiac failure.